(Q33424116)

26 July 2017

title

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden (English)

1 reference

cost-effectiveness analysis

26 July 2017

0 references

1 reference

1 reference

1 reference

Peter Lindgren

1

0 references

author name string

Pierre Geborek

series ordinal

2

1 reference

26 July 2017

Gisela Kobelt

series ordinal

3

1 reference

26 July 2017

publication date

31 March 2009

1 reference

International Journal of Technology Assessment in Health Care

26 July 2017

published in

1 reference

26 July 2017

volume

25

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

181-189

1 reference

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Switching tumor necrosis factor inhibitors: an opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

The links between joint damage and disability in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Health economic issues in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309090230

7 January 2021

10.1017/S0266462309090230

Identifiers

DOI

1 reference

release_okcotjiurjb7ditkwmkphbzoem

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/okcotjiurjb7ditkwmkphbzoem

24 November 2022

mapped directly with Wikidata item

1 reference